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Abstract
Purpose of review—T follicular helper (Tfh) cells play a critical role as providers of B-cell
help and dysfunction in Tfh/B-cell interactions can lead to autoimmunity or immunodeficiency.
These observations have generated a great deal of interest in understanding how these cells are
affected during HIV infection and how their functional changes might affect antibody responses.
Recent findings—Recent studies have shown that HIV/SIV infection affects both Tfh-cell
frequency and function and suggest that Tfh-cell perturbations might contribute to the relative
inefficiency of HIV-infected individuals to generate broadly neutralizing antibodies (bNAbs).
Summary—The present review will highlight these recent findings addressing the role of Tfh
cells in HIV infection as well as the impact HIV infection has on Tfh and circulating memory Tfh
(cTfh) cell frequency and function.
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Introduction
T follicular helper (Tfh) cells are a specialized subset of CD4 T cells that provides help to B
cells in germinal centers (GCs) [1]. These cells are necessary for GC formation,
immunoglobulin (Ig) class-switch recombination (CSR), somatic hypermutation (SHM) and
differentiation of B cells into long-lived memory B cells and plasma cells [2–10]. GCs are
specialized structures within B-cell follicles where B cells undergo SHM of their Ig variable
(V) region genes to achieve higher affinity against a corresponding antigen conferring
greater protective efficacy and CSR of their constant Ig domain (Fc) which provides
different effector potentials [11–20]. Due to their critical role as providers of B-cell help,
there has been a great deal of interest in understanding how these cells are affected during
HIV infection and how their functional changes alter antibody responses.
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Tfh-cell differentiation is driven by the transcription factor Bcl-6 [21, 22], although IRF4,
BATF, MAF and the recently described Ascl2 are also involved in Tfh-cell differentiation
and function [1, 23–26]. Tfh cells are characterized by their high level of CXCR5, ICOS and
PD-1 [6–9] (described tissue resident Tfh cell subsets are summarized in Table 1) expression
and produce a variety of cytokines including IL-4, IL-10 and IL-21 that are critical for the
survival and differentiation of GC B cells into long-lived memory B cells and plasma cells
[2–10]. Tfh/B-cell interactions are therefore essential for the generation of efficient
neutralizing and non-neutralizing antibody responses [9, 10, 15, 20, 21, 41, 42] and have
attracted a lot of recent interest.
The frequency and function of Tfh cells are tightly controlled under physiological conditions
and their dysregulation can lead to various immune perturbations such as autoimmunity and
immunodeficiency [1, 43–46]. In particular, recent studies have shown that HIV/SIV
infection affects both Tfh-cell frequency and function [34–36, 40] and suggest that Tfh-cell
perturbations might contribute to the relative inefficiency of HIV-infected individuals to
generate bNAbs [32, 40]. Finally, the recently described population of blood circulating
memory Tfh cells (cTfh) might mirror at least in part GC Tfh-cell perturbations [32]. In this
review, we will highlight the recent findings that addressed the role of Tfh cells in HIV
infection as well as the impact HIV infection has on Tfh and cTfh-cell frequency and
function.
Role of Tfh cells in HIV infection
Lymphoid organs are the primary anatomic compartments for HIV/SIV replication and
spreading [47–51] and in situ hybridization clearly indicated that HIV/SIV RNA was
associated with GCs [37, 50, 52,]. In viremic HIV-1 infected individuals, Tfh cells were
shown to contain the highest percentage of CD4 T cells harboring HIV DNA and were the
most efficient in supporting productive infection in vitro [34]. Replication competent HIV
was also readily isolated from Tfh cells in subjects with high and low viremia (<2000 HIV
RNA copies) [34]. In addition, the frequency of Tfh cells was found to correlate with plasma
viremia suggesting that Tfh cells might also be one of the primary sources of circulating
virus or the primary target for HIV infection [34].
Interestingly, recent studies have also shown a relative expansion of Tfh cells during the
viremic phase of both HIV and SIV infection [34–37]. These observations are not surprising
as Tfh cells likely expand in response to cognate antigen, but this is in contrast with their
increased susceptibility to SIV [36, 38] and HIV [34] infection. Indeed, HIV-infected CD4 T
cells can be killed by either direct viral cytopathic effects or by HIV-specific CD8 T cells
[53, 54]. Although the precise mechanism by which Tfh cells could withstand HIV-mediated
depletion is unknown, HIV and SIV-specific CD8 T cells appeared to locate outside GCs
[37, 55], which may in turn facilitate HIV/SIV-infected Tfh-cell accumulation in the
follicles. Recently, a population of regulatory Qa-1-restricted CD8 T cells has been shown to
localize in GCs and dampen Tfh cell development in mice [39]. However, their presence in
human GCs and their role in targeting Tfh cells have not been investigated.
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HIV-1 infected activated CD4 T cells escaping cytotoxic CD8 T cells as well as viral
cytopathic effects can enter a quiescent state and thereby represent a major source of latently
infected cells [56, 57] and a major obstacle for HIV eradication [56–59]. Indeed, estimates
for the half-life of the HIV latent reservoir in the blood indicated that it might take as long as
70 years to completely eradicate the latent reservoir in the presence of fully suppressive
ART [60]. Pioneer studies demonstrated that latently infected cells are relatively rare with a
frequency of about 1 in 106 resting CD4 T cells with no significant difference observed
between blood and lymph nodes [56, 61]. These observations led to the conclusion that cells
from peripheral blood could be appropriately used to study the HIV latent reservoir. Using
this strategy, Chomont et al. have identified central memory (CM; defined by the
CD45RA−CCR7+CD27+) and transitional memory (TM; CD45RA−CCR7−CD27+) CD4 T
cells as major cellular compartments of the latent HIV-1 reservoir in blood [62]. However,
lymphoid organs contain about 98% of the total body lymphocytes [56] which are
phenotypically and functionally distinct from CD4 T-cell populations circulating in the
blood [6]. Therefore, studying HIV-1 latently infected LN memory CD4 T-cell populations
might enable the identification of new cellular compartments that may contribute to the
latent reservoir and help in the discovery of new targets for HIV-1 eradication. In this
context, Yukl et al., are currently investigating the cellular subtype distribution of HIV-1
DNA contained in blood and lymphoid tissues collected from ART treated HIV-infected
individuals and showed that effector memory (EM; CD45RO+CCR7−CD27−) CD4 T cells
generally contained a higher level of HIV DNA than other CD4 T-cell populations in LNs
(CROI 2014, #137). While Tfh cells might be enriched in this EM compartment [6, 8],
further investigation and use of additional markers will be required to highlight the specific
role of Tfh cells in the HIV latent reservoir.
Taken together, while recent studies have clearly demonstrated the preponderant role of Tfh
cells during the viremic phase of HIV/SIV [34, 36] infection, the identification of latently
infected CD4 T-cell reservoirs in the blood and lymph nodes (LNs) and their relationship to
each other remain to be established and will contribute to efforts in finding targets for a
potential cure.
Tfh cell functional alterations during HIV infection
While, HIV-1 infection elicits robust antibody responses to envelope proteins (gp120 and
gp41) [63, 64], only 10–30% of HIV-infected individuals generate potent bNAbs [65–69].
This relative inefficiency to generate bNAbs is partially attributed to HIV-1 structure, which
harbors numerous mechanisms of humoral evasion like sequence variable loops [70],
glycosylation [71] and conformational masking of receptor-binding sites [72]) and by the
fact that HIV-infected individuals develop lymphadenopathies associated with damages to
follicular structures likely affecting B-cell differentiation and affinity maturation [73, 74].
Notably, the aforementioned morphological modifications have also been associated with Ig
and B-cell abnormalities during the course of HIV infection [73]. Numerous B-cell
perturbations appear during HIV infection and although many of these defects are improved
by ART, B-cell responses to HIV specific antigens are diminished [75–81].
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Due to their critical requirement in GC B-cell responses, several groups have investigated
the impact of HIV/SIV infection on Tfh-cell frequency and function [34–37]. These studies
have shown an expansion of Tfh cells in HIV/SIV-infected individuals that correlated
positively with the frequency of GC B-cells and antibody production [34–37]. However,
despite an increase in the frequency of these cells, we have recently shown that Tfh cells
from HIV-infected individuals are functionally impaired and cannot provide adequate B-cell
help [40]. This appeared to be partly due to increased PD-L1 expression by GC B cells
leading to PD-1 triggering on Tfh cells which can affect Tfh cell proliferation, activation,
ICOS expression and IL-21 cytokine secretion. Indeed blocking PD-1 signaling enhanced
antibody production and exogenous IL-21 could rescue antibody responses and plasma cell
generation in vitro [40]. It therefore appears that Tfh-cell function is affected in HIV
infected LNs and might arise due to microenvironmental signals leading to an aberrant
expression of inhibitory molecules.
The recent identification of follicular regulatory T (Tfr) cells that can migrate into follicles
and restrain Tfh-cell differentiation represents another level of regulation in lymphoid
tissues which could affect Tfh-cell function and B-cell responses during HIV infection [82–
86]. Their mechanism of action is unknown but studies in mice indicated that in the absence
of PD-1 and PD-L1 these cells expanded and inhibited Tfh-cell function [87]. In a PD-1/PD-
L1 deregulated environment such as the one in HIV-infected LNs, the function of these cells
might be reduced leading to an expansion of Tfh cells.
A better understanding of Tfh/GC B-cell interactions will have important implications for
the generation of robust HIV-specific B cell responses and for the generation of de novo
humoral responses to infections or vaccination. Clearly, the amount of data currently
available is very limited and further investigation on the impact of HIV infection on Tfh-
mediated B-cell help is required. A better understanding of the mechanisms that are affected
by HIV infection leading to defective Tfh-cell signaling and B-cell responses could provide
a critical framework for the development of novel therapeutics and vaccines and could also
shed some light on the mechanisms responsible for the failure in the majority of HIV-
infected individuals to produce bNAbs and their diminished responses to immunization [88–
90].
Circulating memory Tfh cells
The fate and commitment of Tfh cells is still incompletely understood [91–95]. Indeed,
using a mouse model of acute lymphocytic choriomeningitis virus (LCMV) infection, Hale
et al., showed that both LCMV-specific memory CD4 T cells with Tfh and Th1 commitment
were generated [91]. By using an IL-21 reporter mouse system, Lüthje et al., showed that
Tfh cells gave rise to Tfh-like memory cells that could differentiate into conventional
effector T helper cells or Tfh cells upon antigen recall [93]. Additional studies showed that
Tfh cells could revert in long-lived memory Tfh cells expressing low levels of Bcl6, CXCR5
and PD-1 expression in the absence of antigen [92, 95]. Choi et al. also confirmed the
capacity of Tfh cells to form memory and showed that Tfh cells shared phenotypic
characteristics with memory precursor CD8 T cells [96]. Overall, these studies demonstrated
that at least in mice, a fraction of Tfh cells have the capacity to become memory cells and
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can promote GC formation and antibody production more effectively than non-Tfh cells
upon antigenic challenge [91–95].
Initial evidence for memory cTfh cells in humans came from studies of human malignancies
[27, 28, 97]. A more comprehensive study by Morita et al. further defined a population of
memory Tfh-like cells with an enhanced capacity to provide naïve and memory B-cell help
[29]. This study subdivided circulating Tfh-like cells into three subsets (Th1, Th2 and Th17-
like) based on their expression or the lack of CXCR3 and CCR6 and demonstrated that both
the Th2 and Th17-like cells (CXCR3−CCR6− and CXCR3−CCR6+ respectively) efficiently
helped naïve B cells and differentially modulated isotype switching while Th1-like subset
(CXCR3+) did not provide adequate help to naïve B cells (described circulating Tfh-like cell
subsets are summarized in Table 1). The presence of blood central memory CD4 T cells
expressing CXCR5 and CXCL13 and efficiently induced plasma cell differentiation and
antibody secretion further supported the existence of cTfh cells [30].
Studies of memory cTfh cells in the context of HIV infection have been scarce but they have
suggested that the capacity of these cells to provide B-cell help might be compromised [31–
33, 98]. Indeed, Pallikkuth et al. assessed H1N1/09 influenza responses induced following
vaccination in HIV-uninfected and HIV infected individuals under ART and showed that
half of HIV-infected vaccinees did not respond to the immunization. Based on this
observation, the authors assessed cTfh-cell capacity to produce IL-21, CXCL-13 and express
ICOS, and concluded that cTfh cells from non-responders were functionally impaired
(reduced IL-21 secretion and ICOS expression) [31].
A more recent study identified a population of memory CD4+CXCR5+ T cells
(CCR6hiPD-1hi) that produced IL-21 and supported B cell differentiation [33]. This study
found that the frequency of these cells was decreased in treatment naïve HIV infected
individuals but was recovered after antiretroviral therapy. Additionally, this study also found
decreased antibody production and a reduced frequency of IL-2, IL-17 and IL-21 producing
CD4+CXCR5+CCR6hiPD-1hi cells in HIV infected when compared to uninfected controls.
The relationship between these circulating Tfh-like cells and those previously described by
other studies [29, 30, 32,] is unknown. However, analysis of Tfh-associated genes showed
that these cells more closely resembled non-Tfh memory cells as opposed to GC Tfh cells
[33].
In addition, Locci et al. showed that memory CXCR5+CXCR3−PD-1+ CD4+ T cells were
closely related to GC Tfh cells based on gene expression and cytokine profiles and their
capacity to provide B-cell help [32]. Interestingly, the frequency of these cells positively
correlated with the development of bNAbs in HIV-infected subjects [32], suggesting that the
frequency of cTfh cells could be indicative of enhanced and probably efficient GC
responses. In contrast, Boswell et al. showed that the frequencies of cTfh cells (defined by
CXCR5+CCR6hiPD-1hi expression) in untreated HIV infected did not correlate with the
frequencies of memory B cells or with Ig neutralizing activity [33]. This lack of
concordance between the two studies likely arises from differences in the patient samples
studied as well as the markers of cTfh used.
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Taken together, the use of cTfh-cell frequency and function as an indirect marker of GC Tfh
cells or ongoing GC reactions represents a very interesting tool, but will require additional
investigation in order to improve their definition and harmonize their assessment.
Conclusion
The past few years have witnessed considerable findings with regards to Tfh cells and HIV
pathogenesis. However, it is clear that intense investigation will be needed in order to better
understand the mechanisms in charge of both Tfh and cTfh cell dysfunctions during the
course of HIV infection and to determine the role of these cells during HIV infection. The
progressive characterization of Tfh and cTfh cells will also be highly useful to elucidate the
impact of HIV infection on the generation of efficient HIV-specific B-cell responses.
Interestingly, as recently suggested [32], cTfh cells might be valuable indicators of vaccine-
induced B-cell responses [31, 32, 98, 99].
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• Tfh cells serve as the major CD4 compartment for HIV-1 infection, replication
and production. Yet, their role in establishing and forming part of the latent
reservoir remains to be elucidated.
• While Tfh-cell frequencies are increased during the viremic phase of HIV
infection, Tfh cells are functionally impaired and cannot provide adequate B-
cell help.
• The presence of blood circulating memory Tfh-like cells has recently been
described. Their actual relationship to GC Tfh cells still requires further
investigation but a population of these cells has been shown to be closely related
phenotypically and functionally to GC Tfh cells and their frequency correlated
with the development of potent bNAbs in HIV-infected individuals.
• Recent studies have suggested that the function of circulating memory Tfh cells
might be impaired in HIV infected subjects but this requires further
investigation.
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Table 1
Described phenotypes of circulating Tfh-like cells subsets and tissue resident Tfh cell subsets.
Phenotype Model Tissue References
Circulating Tfh-like cell subsets
CD45RO+CXCR5+ Human Blood [27] Bossaller et al.
CXCR5+ with increased ICOS/PD-1 expression in SLE patients Human Blood [28] Simpson et al.
CD45RA−CXCR5+ subdivided into CXCR3−CCR6+, CXCR3−CCR6− and
CXCR3+CCR6− cells
Human Blood [29] Morita et al.
CD45RA−CCR7+CXCR5+ Human Blood [30] Chevalier et al.
CD45RA−CXCR5+ Human Blood [31] Pallikkuth et al.
CD45RO+CXCR5+CXCR3−PD-1+ Human Blood [32] Locci et al.
CD27hiCD45ROhiCCR7hiCXCR5hiCCR6hiPD-1hi Human Blood [33] Boswell et al.
Tissue resident Tfh cell subsets
CD45RA−CXCR5+PD-1hi Human LN [34] Perreau et al.
CXCR5+PD-1hi Human LN [35] Linqvist et al.
CCR7lowPD-1hiICOShi Macaques LN [36] Petrovas et al.
CD3+PD-1hi (in situ) Macaques LN [37] Hong et al.
CD45RA−PD-1hiCD127low Macaques Spleen and LN [38] Xu et al.
CD45RA−CXCR5+CD57+ Human Tonsils [39] Kim et al.
CXCR5+ICOS+ Human Tonsils [8] Breitfeld et al.
CD45RA−CXCR5hi Human Tonsils and LN [40] Cubas et al.
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